聯邦制藥(03933.HK):阿爾茨海默型痴呆治療用藥鹽酸美金剛通過一致性評價
格隆匯6月7日丨聯邦制藥(03933.HK)發佈公吿,公司全資附屬公司珠海聯邦制藥股份有限公司中山分公司生產的鹽酸美金剛片(10mg)經中國國家藥品監督管理局審批,通過仿製藥質量和療效一致性評價。
根據披露,鹽酸美金剛為神經系統用藥,適用於治療中重度至重度阿爾茨海默型痴呆,為2020年版國家醫保目錄乙類藥品。本次獲批將進一步有助於該公司在神經系統領域的業務擴展。該公司將持續致力於新產品研發及推進一致性評價,預期將為該公司及其股東創造更大收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.